Liver Transplantation for Hepatocellular Carcinoma in Patients with Inherited Metabolic Liver Diseases: A Single-Center Analysis

Basit Öğe Kaydı
dc.authoridGARZALI, IBRAHIM UMAR/0000-0002-9797-851X;
dc.authorwosidGARZALI, IBRAHIM UMAR/ITU-1475-2023
dc.authorwosidHargura, Abdirahman Sakulen/GQQ-8646-2022
dc.contributor.authorGarzali, Ibrahim Umar
dc.contributor.authorHargura, Abdirahman Sakulen
dc.contributor.authorInce, Volkan
dc.contributor.authorVarol, Fatma Ilknur
dc.contributor.authorCarr, Brian I.
dc.contributor.authorYilmaz, Sezai
dc.date.accessioned2024-08-04T20:10:23Z
dc.date.available2024-08-04T20:10:23Z
dc.date.issued2023
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground/Aims: Liver transplantation is an acceptable treatment for some selected hepatocellular carcinoma. We report our experi-ence of 6 patients with liver transplantation for hepatocellular carcinoma with background inherited metabolic disease. Materials and Methods: This is a single-center retrospective, descriptive study. Consecutive patients who underwent liver transplanta-tion for hepatocellular carcinoma with background inherited metabolic disease were included in the study. The record of the patients was accessed, and the following data were extracted: sociodemographic variables, type of metabolic disease, date of liver transplan-tation, tumor characteristics, laboratory parameters, Model for End-Stage Liver Disease score, immediate-and long-term outcome after transplantation, disease-free survival, and overall survival. Data were analyzed using Statistical Package for the Social Sciences version 25.0. Results: Six patients received liver transplantation for hepatocellular carcinoma with background inherited metabolic liver disease. The median age was 4.5 years. The median Model for End-Stage Liver Disease score was 29.30. The median maximum tumor diameter was 2.15 cm. Three patients had multiple tumor nodules. Half of the patients had microvascular invasion. Four of the patients had a mod-erately differentiated tumor. Progressive familial intrahepatic cholestasis type II is the commonest inherited metabolic disease seen in 3 patients. Median follow-up is 46.1 months. Half of the patients are currently more than 5 years post liver transplantation with no features of recurrence. The estimated survival rates at 1, 3, and 5 years are 100%, 83.3%, and 83.3%, respectively. Conclusion: Liver transplant for these categories of patients is associated with good disease-free and overall survival, even in the pres-ence of some seemingly poor prognostic features.en_US
dc.identifier.doi10.5152/tjg.2023.22679
dc.identifier.issn2148-5607
dc.identifier.issue12`en_US
dc.identifier.pmid37681267en_US
dc.identifier.scopus2-s2.0-85179848862en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.trdizinid1241082en_US
dc.identifier.urihttps://doi.org/10.5152/tjg.2023.22679
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1241082
dc.identifier.urihttps://hdl.handle.net/11616/92755
dc.identifier.volume34en_US
dc.identifier.wosWOS:001127637800002en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofTurkish Journal of Gastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectLiver transplantationen_US
dc.subjecthepatocellular carcinomaen_US
dc.subjectinherited metabolic liver diseasesen_US
dc.subjectprogressive familial intrahepatic cholestasisen_US
dc.titleLiver Transplantation for Hepatocellular Carcinoma in Patients with Inherited Metabolic Liver Diseases: A Single-Center Analysisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu